€11.58
Your prediction
Intellia Therapeutics Inc Stock
Pros and Cons of Intellia Therapeutics Inc in the next few years
Pros
Cons
Performance of Intellia Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Intellia Therapeutics Inc | 7.830% | 11.513% | 41.227% | -52.464% | 1.848% | -81.931% | -29.592% |
Chromadex Corp | -4.910% | -9.884% | -33.190% | 163.605% | 50.485% | 317.003% | 76.941% |
Polynovo Ltd | 3.680% | 6.015% | 14.634% | -53.311% | -41.736% | -28.788% | -46.992% |
Cardio3 Biosciences S.A. | 4.790% | 3.470% | -13.456% | 53.271% | -50.378% | -78.618% | -96.431% |
Comments
News

Analysts Think These Stocks Could More Than Double in Value
Persistent volatility has plagued the S&P 500 for much of 2025, prompting widespread caution among many investors amid the uncertainties of trade battles, tariffs, domestic policy, and more

Intellia Therapeutics Delivers a Q4 Beat
Intellia Therapeutics (NASDAQ:NTLA), a leader in gene-editing technology, delivered its fourth-quarter earnings results on Feb. 27. The company reported a net loss of $1.27 per share, which was

2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
Biotech companies can skyrocket in a short period because of excellent clinical or regulatory progress. And if we take the word of Wall Street analysts, some of them will do precisely that in the